AD2
MCID: ALZ037
MIFTS: 52

Alzheimer Disease-2 (AD2) malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Mental diseases

Aliases & Classifications for Alzheimer Disease-2

Aliases & Descriptions for Alzheimer Disease-2:

Name: Alzheimer Disease-2 54 12 13
Ad2 12 50 24 66
Alzheimer Disease 2 66 29 69
Alzheimer Disease Associated with Apoe4 12 66
Late-Onset Familial Alzheimer Disease 50 24
Late Onset Alzheimer Disease 50 52
Alzheimer Disease Type 2 50 24
Alzheimer's Disease 2 12 14
Alzheimer Disease Associated with Apoe E4 50
Late Onset Familial Alzheimer Disease 50
Alzheimer Disease 2, Late Onset 12
Alzheimer Disease, Late Onset 69
Late-Onset Alzheimer Disease 66
Familial Senile Dementia 24
Lofad 50
Ad 2 24

Characteristics:

HPO:

32
alzheimer disease-2:
Onset and clinical course late onset


Classifications:



External Ids:

OMIM 54 104310
Disease Ontology 12 DOID:0110035
ICD10 33 G30
MedGen 40 C1863051
MeSH 42 D000544

Summaries for Alzheimer Disease-2

NIH Rare Diseases : 50 late-onset familial alzheimer disease, is a form of familial alzheimer disease, that begins after age 65. in general, alzheimer disease (ad) is a degenerative disease of the brain that causes gradual loss of memory, judgement and the ability to function socially. the exact underlying cause of late-onset familial ad is not completely understood; however, researchers suspect that it is a complex condition, which is likely associated with multiple susceptibility genes in combination with environmental and lifestyle factors. a gene called apoe has been studied extensively as a risk factor for the disease. in particular, a variant of this gene called the "e4 allele" seems to increase an individual's risk for developing late-onset alzheimer disease (people who have this allele are said to have the late-onset familial ad type 2). it is important to understand that apoe is a susceptibility gene, not a determinative gene, which means that people  having two copies of this allele have an increased risk of having ad but not necessarily will have it.  there is no cure for ad. treatment is supportive and based on the signs and symptoms present in each person. last updated: 5/5/2017

MalaCards based summary : Alzheimer Disease-2, also known as ad2, is related to alzheimer disease and keratosis palmoplantaris striata, and has symptoms including dementia, parkinsonism and neurofibrillary tangles. An important gene associated with Alzheimer Disease-2 is APOE (Apolipoprotein E), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Development HGF signaling pathway. The drugs Estradiol and Medroxyprogesterone acetate have been mentioned in the context of this disorder. Affiliated tissues include brain, and related phenotypes are cellular and growth/size/body region

UniProtKB/Swiss-Prot : 66 Alzheimer disease 2: A late-onset neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C- terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death.

Disease Ontology : 12 An Alzheimer's disease that is characterized by an association of the apolipoprotein E E4 allele.

Description from OMIM: 104310

Related Diseases for Alzheimer Disease-2

Diseases in the Alzheimer Disease family:

Alzheimer Disease-4 Alzheimer Disease 17
Alzheimer Disease 12 Alzheimer Disease, Type 3
Alzheimer Disease 18 Alzheimer Disease-2
Alzheimer Disease 19, Late Onset Alzheimer Disease 16
Alzheimer's Disease 7 Alzheimer's Disease 11
Alzheimer's Disease 13 Alzheimer's Disease 14
Alzheimer's Disease 15 Early-Onset Familial Alzheimer Disease
Alzheimer Disease Type 1 Early-Onset, Autosomal Dominant Alzheimer Disease
Alzheimer Disease Risk Factor

Diseases related to Alzheimer Disease-2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
id Related Disease Score Top Affiliating Genes
1 alzheimer disease 11.2
2 keratosis palmoplantaris striata 10.3 APOE MAPT
3 mechanical entropion 10.3 APOE NOS3
4 mcleod neuroacanthocytosis syndrome 10.3 MAPT PSEN1
5 gata1-related thrombocytopenia 10.3 MAPT PSEN1
6 hereditary paraganglioma-pheochromocytoma syndromes 10.2 MAPT PSEN1
7 encephalitozoonosis 10.2 APOE APP PSEN1
8 combined oxidative phosphorylation deficiency 8 10.2 APOE PSEN2
9 ectodermal dysplasia mental retardation syndactyly 10.2 APP PSEN1 PSEN2
10 foxp2-related speech and language disorders 10.2 APP PSEN1 PSEN2
11 bone dysplasia azouz type 10.2 APOE APP MAPT
12 cardiomyopathy, dilated, 1v 10.2 APP PSEN1 PSEN2
13 severe congenital nemaline myopathy 10.2 APOE MAPT PSEN1
14 intracranial structure hemangioma 10.2 APP MAPT PSEN1
15 meier-gorlin syndrome 5 10.2 APOE APP MAPT
16 autoimmune disease of urogenital tract 10.2 APOE MAPT PSEN1
17 pulmonary systemic sclerosis 10.2 APOE MAPT SERPINA3
18 gastric adenosquamous carcinoma 10.1 CTSD SERPINA3
19 acne inversa, familial, 3 10.1 APOE MAPT PSEN1
20 ichthyosis lamellar 2 10.1 APOE APP MAPT
21 cerebroretinal vasculopathy 10.1 MAPT PSEN1
22 angina pectoris 10.1 APOE MAPT PSEN1
23 acrofrontofacionasal dysostosis 10.1 BCHE MAPT PSEN1
24 postauricular lymphadenitis 10.1 BCHE MAPT PSEN1
25 rete testis neoplasm 10.1 PLAU SERPINA3
26 mitochondrial dna depletion syndrome 14, cardioencephalomyopathic type 10.1 APP MAPT MT-ND2
27 hard palate cancer 10.1 APOE APP PSEN1
28 limited scleroderma 10.1 APOE APP PSEN1 SERPINA3
29 polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract 10.1 APOE APP PSEN1 SERPINA3
30 vulvar eccrine adenocarcinoma 10.1 APP MAPT SERPINA3
31 epithelioid type angiomyolipoma 10.1 APOE APP MAPT PSEN1
32 allergic bronchopulmonary aspergillosis, familial 10.1 APOE APP MAPT SERPINA3
33 urethritis 10.0 APOE PSEN1
34 personality disorder 10.0 APOE MAPT PSEN1
35 cardiomyopathy, dilated, 1u 10.0 APOE APP MAPT PSEN1 PSEN2
36 coenzyme q10 deficiency, primary, 1 9.9 APOE APP BCHE MAPT PSEN1
37 amelogenesis imperfecta, type iia3 9.9 APP TCF3
38 pick disease 9.9 APP PSEN1 PSEN2 TCF3
39 eumycotic mycetoma 9.8 APOE APP BCHE MAPT PSEN1 PSEN2
40 substance-induced psychosis 9.8 APOE APP BCHE MAPT PSEN1 PSEN2
41 contagious pustular dermatitis 9.8 APOE APP BCHE MAPT PSEN1 SERPINA3
42 camptodactyly-arthropathy-coxa vara-pericarditis syndrome 9.7 APOE CETP CTSD MT-ND2
43 spondyloarthropathy 1 8.7 APOE APP BCHE CETP CTSD GSK3B
44 meckel syndrome 10 8.2 APOE APP BCHE CETP CTSD GSK3B

Graphical network of the top 20 diseases related to Alzheimer Disease-2:



Diseases related to Alzheimer Disease-2

Symptoms & Phenotypes for Alzheimer Disease-2

Symptoms by clinical synopsis from OMIM:

104310

Clinical features from OMIM:

104310

Human phenotypes related to Alzheimer Disease-2:

32
id Description HPO Frequency HPO Source Accession
1 dementia 32 HP:0000726
2 parkinsonism 32 HP:0001300
3 neurofibrillary tangles 32 HP:0002185
4 long-tract signs 32 HP:0002423
5 alzheimer disease 32 HP:0002511

MGI Mouse Phenotypes related to Alzheimer Disease-2:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.24 APOE APP CTSD MAPT MT-ND2 NOS3
2 growth/size/body region MP:0005378 10.22 NOS3 PLAU PSEN1 PSEN2 TCF3 APOE
3 behavior/neurological MP:0005386 10.21 APOE APP CTSD GSK3B MAPT NOS3
4 homeostasis/metabolism MP:0005376 10.21 APOE APP BCHE CTSD GSK3B IDE
5 cardiovascular system MP:0005385 10.2 PSEN2 APOE CTSD GSK3B IDE MAPT
6 immune system MP:0005387 10.14 APOE APP CTSD GSK3B MAPT MT-ND2
7 hematopoietic system MP:0005397 10.11 APOE APP CTSD MAPT NOS3 PLAU
8 endocrine/exocrine gland MP:0005379 10.1 APOE CTSD GSK3B NOS3 PLAU PSEN1
9 mortality/aging MP:0010768 10.06 BCHE CTSD GSK3B MAPT NOS3 PLAU
10 digestive/alimentary MP:0005381 10.05 APOE CTSD GSK3B NOS3 PLAU PSEN1
11 craniofacial MP:0005382 10 PSEN1 PSEN2 GSK3B IDE MAPT PLAU
12 nervous system MP:0003631 10 APP CTSD GSK3B IDE MAPT NOS3
13 integument MP:0010771 9.97 APOE APP CTSD IDE MAPT PSEN1
14 normal MP:0002873 9.7 APP GSK3B MAPT NOS3 PSEN1 PSEN2
15 renal/urinary system MP:0005367 9.5 NOS3 PSEN1 PSEN2 TCF3 APOE GSK3B
16 vision/eye MP:0005391 9.17 APOE CTSD MAPT NOS3 PLAU PSEN1

Drugs & Therapeutics for Alzheimer Disease-2

Drugs for Alzheimer Disease-2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 227)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757 53477783
2
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
3
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
4
Rivastigmine Approved, Investigational Phase 4,Phase 3 123441-03-2 77991
5
Donepezil Approved Phase 4,Phase 3,Phase 2 120014-06-4 3152
6
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
7
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
8
Ondansetron Approved Phase 4 99614-02-5 4595
9
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
10
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
11
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
12
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
13
Benzocaine Approved Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
14
Metformin Approved Phase 4,Phase 2 657-24-9 14219 4091
15 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3
16 Antineoplastic Agents, Hormonal Phase 4
17 Contraceptive Agents Phase 4
18 Contraceptive Agents, Male Phase 4
19 Estradiol 17 beta-cypionate Phase 4
20 Estradiol 3-benzoate Phase 4
21 Estradiol valerate Phase 4 979-32-8
22 Estrogens Phase 4,Phase 2,Phase 1
23 Hormone Antagonists Phase 4,Phase 2,Phase 1
24 Hormones Phase 4,Phase 2,Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
26
Medroxyprogesterone Phase 4 520-85-4 10631
27 Phytoestrogens Phase 4,Phase 2,Phase 1
28 Polyestradiol phosphate Phase 4
29 Progestins Phase 4
30 Autonomic Agents Phase 4,Phase 3
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1
33 Cholinergic Agents Phase 4,Phase 3,Phase 2
34 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2
35 Nootropic Agents Phase 4,Phase 3,Phase 2
36 Anesthetics Phase 4
37 Anesthetics, General Phase 4
38 Anesthetics, Inhalation Phase 4
39 Anti-Anxiety Agents Phase 4
40 Antiemetics Phase 4
41 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1
42 Antipruritics Phase 4
43 Antipsychotic Agents Phase 4,Phase 3
44 BB 1101 Phase 4
45 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
46 Dermatologic Agents Phase 4,Phase 1,Phase 2
47 Dexamethasone 21-phosphate Phase 4
48 Dexamethasone acetate Phase 4 1177-87-3
49 Gastrointestinal Agents Phase 4
50 glucocorticoids Phase 4

Interventional clinical trials:

(show top 50) (show all 199)
id Name Status NCT ID Phase
1 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4
2 Depth of Hypnosis and Postoperative Nausea and Vomiting During Xenon Anaesthesia Completed NCT00793663 Phase 4
3 Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 Completed NCT00948766 Phase 4
4 A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints Completed NCT00276510 Phase 4
5 Memantine Versus Donepezil in Early Stages of Alzheimer's Disease Completed NCT00505167 Phase 4
6 Corticolimbic Degeneration and Treatment of Dementia Completed NCT00768261 Phase 4
7 Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease Completed NCT00549601 Phase 4
8 Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome Completed NCT01112683 Phase 4
9 A Comparison of Two Standard Therapies in the Management of Dementia With Agitation Completed NCT00208819 Phase 4
10 Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study Recruiting NCT02409238 Phase 4
11 A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type. Not yet recruiting NCT02989402 Phase 4
12 Safety and Tolerability of Donepezil in Mild to Moderate Alzheimer's Disease Not yet recruiting NCT02787746 Phase 4
13 Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) Withdrawn NCT01822951 Phase 4
14 Donepezil Treatment of Psychotic Symptoms in Dementia Patients Unknown status NCT00190021 Phase 3
15 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
16 Depression in Alzheimer's Disease-2 Completed NCT00086138 Phase 2, Phase 3
17 Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease Completed NCT00348140 Phase 3
18 Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease Completed NCT00428090 Phase 3
19 Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's Completed NCT00105547 Phase 3
20 A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease Completed NCT01404169 Phase 3
21 Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type Completed NCT01438060 Phase 3
22 A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease Completed NCT00818662 Phase 3
23 Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease Completed NCT02035982 Phase 3
24 Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease Completed NCT00646269 Phase 3
25 Project ACT: Advancing Caregiving Techniques Completed NCT00259480 Phase 3
26 Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type Recruiting NCT02168920 Phase 3
27 Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type Recruiting NCT02446132 Phase 3
28 Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type Recruiting NCT02442765 Phase 3
29 Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type Recruiting NCT02442778 Phase 3
30 Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia) Recruiting NCT03160027 Phase 2, Phase 3
31 An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Recruiting NCT02245737 Phase 2, Phase 3
32 A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease_ Recruiting NCT03036280 Phase 3
33 Risk Reduction for Alzheimer's Disease Recruiting NCT02913664 Phase 2, Phase 3
34 Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium Recruiting NCT02928692 Phase 3
35 A Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Active, not recruiting NCT01862640 Phase 3
36 Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Active, not recruiting NCT01922258 Phase 3
37 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Active, not recruiting NCT01760005 Phase 2, Phase 3
38 Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type Terminated NCT00160147 Phase 3
39 Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's Terminated NCT00322036 Phase 3
40 A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease Terminated NCT00679627 Phase 3
41 Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type Terminated NCT02248116 Phase 2, Phase 3
42 Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Unknown status NCT00003453 Phase 2
43 Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha Unknown status NCT00031018 Phase 2
44 Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease Unknown status NCT00154635 Phase 2
45 Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease Unknown status NCT00174525 Phase 2
46 Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication Completed NCT00117650 Phase 2
47 Physiotherapy on the Airway of Bruxist Children Completed NCT01178229 Phase 1, Phase 2
48 Pioglitazone in Alzheimer Disease Completed NCT00982202 Phase 2
49 Metformin in Amnestic Mild Cognitive Impairment Completed NCT00620191 Phase 2
50 A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia Completed NCT02185053 Phase 2

Search NIH Clinical Center for Alzheimer Disease-2

Genetic Tests for Alzheimer Disease-2

Genetic tests related to Alzheimer Disease-2:

id Genetic test Affiliating Genes
1 Alzheimer Disease 2 29
2 Late-Onset Familial Alzheimer Disease 24
3 Alzheimer Disease Type 2 24 APOE

Anatomical Context for Alzheimer Disease-2

MalaCards organs/tissues related to Alzheimer Disease-2:

39
Brain

Publications for Alzheimer Disease-2

Variations for Alzheimer Disease-2

ClinVar genetic disease variations for Alzheimer Disease-2:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 NOS3 NM_000603.4(NOS3): c.894T> G (p.Asp298Glu) single nucleotide variant risk factor rs1799983 GRCh37 Chromosome 7, 150696111: 150696111
2 APOE NM_000041.3(APOE): c.388T> C (p.Cys130Arg) single nucleotide variant Pathogenic rs429358 GRCh37 Chromosome 19, 45411941: 45411941

Expression for Alzheimer Disease-2

Search GEO for disease gene expression data for Alzheimer Disease-2.

Pathways for Alzheimer Disease-2

Pathways related to Alzheimer Disease-2 according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.2 APOE APP GSK3B IDE MAPT MT-ND2
2
Show member pathways
12.6 GSK3B NOS3 PLAU PSEN1 PSEN2
3
Show member pathways
12.36 GSK3B MAPT PSEN1 PSEN2
4 12.24 APOE APP GSK3B MAPT PSEN1 PSEN2
5 11.82 APP GSK3B PSEN1 PSEN2
6 11.74 APOE APP GSK3B MAPT
7 11.4 APP GSK3B MAPT
8 11.32 APP CTSD GSK3B PSEN1 PSEN2
9 11.26 CTSD GSK3B PSEN2
10 11.04 APOE APP IDE
11 10.92 GSK3B TCF3
12 10.77 APP CTSD IDE PSEN1 PSEN2
13 10.75 APOE APP GSK3B MAPT PSEN1 PSEN2
14 10.18 PSEN1 PSEN2

GO Terms for Alzheimer Disease-2

Cellular components related to Alzheimer Disease-2 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.65 APOE GSK3B MAPT PSEN1 PSEN2
2 high-density lipoprotein particle GO:0034364 9.46 APOE CETP
3 nuclear envelope lumen GO:0005641 9.4 APP BCHE
4 ciliary rootlet GO:0035253 9.37 APP PSEN1
5 dendritic shaft GO:0043198 9.33 APP GSK3B PSEN1
6 membrane-bounded organelle GO:0043227 9.32 GSK3B PSEN1
7 growth cone GO:0030426 9.26 APP GSK3B MAPT PSEN1
8 extracellular space GO:0005615 9.23 APOE APP BCHE CETP CTSD IDE
9 extracellular region GO:0005576 10.03 APOE APP BCHE CETP CTSD IDE

Biological processes related to Alzheimer Disease-2 according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.98 CTSD IDE PLAU PSEN1 PSEN2
2 response to oxidative stress GO:0006979 9.77 APOE APP PSEN1
3 Notch signaling pathway GO:0007219 9.72 APP PSEN1 PSEN2
4 positive regulation of catalytic activity GO:0043085 9.69 APOE PSEN1 PSEN2
5 cholesterol metabolic process GO:0008203 9.67 APOE APP CETP
6 positive regulation of dendritic spine development GO:0060999 9.62 APOE PSEN1
7 vasodilation GO:0042311 9.61 APOE NOS3
8 membrane protein ectodomain proteolysis GO:0006509 9.61 PSEN1 PSEN2
9 regulation of protein binding GO:0043393 9.6 APP PSEN1
10 nitric oxide mediated signal transduction GO:0007263 9.58 APOE NOS3
11 reverse cholesterol transport GO:0043691 9.57 APOE CETP
12 high-density lipoprotein particle remodeling GO:0034375 9.56 APOE CETP
13 Notch receptor processing GO:0007220 9.54 PSEN1 PSEN2
14 low-density lipoprotein particle remodeling GO:0034374 9.52 APOE CETP
15 amyloid precursor protein metabolic process GO:0042982 9.48 APOE PSEN1
16 negative regulation of platelet activation GO:0010544 9.46 APOE NOS3
17 amyloid precursor protein catabolic process GO:0042987 9.43 PSEN1 PSEN2
18 amyloid fibril formation GO:1990000 9.4 APP MAPT
19 very-low-density lipoprotein particle remodeling GO:0034372 9.37 APOE CETP
20 cellular response to beta-amyloid GO:1904646 9.32 APP PSEN1
21 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.26 APP PSEN1
22 astrocyte activation involved in immune response GO:0002265 9.16 APP PSEN1
23 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 8.96 APP PSEN1
24 beta-amyloid metabolic process GO:0050435 8.8 IDE PSEN1 PSEN2

Molecular functions related to Alzheimer Disease-2 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.65 CTSD IDE PLAU PSEN1 PSEN2
2 lipid transporter activity GO:0005319 9.37 APOE CETP
3 cholesterol transporter activity GO:0017127 9.32 APOE CETP
4 lipoprotein particle binding GO:0071813 9.16 APOE MAPT
5 beta-amyloid binding GO:0001540 9.13 APOE BCHE IDE
6 aspartic-type endopeptidase activity GO:0004190 8.8 CTSD PSEN1 PSEN2

Sources for Alzheimer Disease-2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....